NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS  «  1  2  3  4  5  » 
»04/06/2007 [Independent reports]
Project Overview: Assessing GLP Compliance and Quality Practices in China

Taken from CHA's website...   more»

Amgen »22/05/2007 [Company watch]
Amgen (NASDAQ:AMGN) today announced that David Lacey, M.D., has been named senior vice president, head of Research, effective immediately.

Amgen (NASDAQ:AMGN) today announced that David Lacey, M.D., has been named senior vice president, head of Research, effective immediately. Over the past year, Lacey acted as the interim head of Research -- in addition to his role as Amgen South San Francisco site leader -- and demonstrated his ability to effectively manage Amgen's global Research organization, encompassing the company's Oncology/Hematology, Inflammation, Metabolic Disorders and Neuroscience therapeutic areas...   more»

GlaxoSmithKline »24/05/2007 [Company watch]
GlaxoSmithKline launches Chinese R&D centre with appointment of head in Shanghai

Jingwu Zang to lead work on neurogenerative diseases GlaxoSmithKline (GSK) today announces the appointment of Jingwu Zang to head a new GSK research and development centre in Shanghai, China. His appointment, as Senior Vice President, will be effective in June....   more»

Pfizer »24/05/2007 [Industry news]
Pfizer Says Research and Development Head John LaMattina Will Retire This Year

Pfizer said today that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company‚Äôs research division throughout his 30-year career, will retire from Pfizer by the end of this year. The company will begin a search both inside and outside the company for his successor, and Dr. LaMattina has agreed to remain during this period to ensure a smooth transition....   more»

Merck & Co »20/05/2007 [Industry news]
Merck Announces Resignation of Peter Loescher, President, Global Human Health

WHITEHOUSE STATION, N.J., May 20, 2007 - Merck & Co., Inc. today announced the resignation of Peter Loescher, president, Global Human Health. Effective July 1, 2007, Mr. Loescher, 49, will take on the position of president and chief executive officer at Siemens AG. "We thank Peter for his contributions to Merck and wish him and his family well in this new endeavor," said Richard T. Clark, chairman, president and chief executive officer. "Merck remains fully committed to the strategic initiatives and operating goals established for the Global Human Health (GHH) organization. We continue to be pleased with the strong business performance across all the GHH franchises and regions, and we are confident that it will continue." Mr. Loescher will remain for a period of time to help with the leadership transition. Merck expects to name a new leader for the GHH organization so...   more»

»29/05/2007 [Industry news]
China sentences former drug official to death

China has today sentenced to death the former director of its State Food and Drug Administration (SFDA), on charges of corruption, according to reports in the Chinese media...   more»

GlaxoSmithKline »29/05/2007 [Company watch]
GlaxoSmithKline set up a drug research centre in China.

GlaxoSmithKline (GSK) is the latest pharma heavyweight to set up a drug research centre in China....   more»

»24/05/2007 [Industry news]
Gates Foundation Opens Beijing Office To Increase HIV Prevention Efforts In China

The Bill & Melinda Gates Foundation has opened an office in Beijing to increase HIV prevention efforts in China and control the spread of the virus in the country....   more»

Bridgetech Holdings »29/05/2007 [Company watch]
Bridgetech Forms Strategic Alliance With ValiRx Plc to Foster Technology Transfer Between Europe and Greater China

Bridgetech Holdings International, Inc. a company focused on maximizing the potential of emerging healthcare products and services in the U.S. and Asian markets, today announced that it has signed a strategic alliance agreement with ValiRx plc, a biopharmaceutical company based in England. The agreement governs cooperative efforts in creating and exploiting market and technology transfer initiatives between Europe and Greater China....   more»

»04/06/2007 [Finance]
Biggest fall in China's shares in a single day

China's stock market recorded the biggest ever one day fall. Despite this other markets around the world remained unaffected, with some actually recording rises. The CSI 300 index dropped almost 8% caused tthey say by Government warnings and their recently imposed trebling of stamp duty on share trading....   more»

Eli Lilly & Co »06/06/2007 [Company watch]
BioVeda China to Receive $10 Million Investment from Lilly Asian Ventures

BioVeda China today announced a $10 Million investment from Lilly Asian Ventures. BioVeda China is the first international venture capital fund focusing on life-sciences investments in China. The investment has shown Lilly's commitment to expand its economic footprint in the fast growing life-science industry in China....   more»

»25/05/2007 [Industry news]
Siemens joins hospital venture

German conglomerate Siemens and hospital operator Asklepios Kliniken yesterday signed an agreement with Tongji University to jointly build a 1-billion-yuan Sino-German Friendship Hospital in Shanghai....   more»

»11/06/2007 [Industry news]
Chinese Drug/Food Safety Plan Announced

In a bid to better control the current poor levels of regulation within the drug and food sectors, the Chinese Government is set to implement a long-term plan, designed to combat bad foods and dangerous medicines. The offensive, with a planned duration of five years, was announced amid a recent flurry of national and international health scandals that have exposed China's lackadaisical approach to regulation at present. Products that have been identified as sub-standard include locally produced medicines, toothpaste, pet foods and farm produce. China has come under much fire, particularly from the US, which has highlighted China's infiltration of the worldwide marketplace with fake products; these, it alleges, potentially endangering consumer health. Indeed, officials in Panama are adamant that around 100 deaths there have been caused by drug ingredients imported from China. The US recently prohibited certain Chinese-produced animal feed, on account of it containing an illegal additive in vegetable protein, which can on occasion be addictive. The most recent country to lambast Chinese product is Singapore, which only last week banned a selection of toothpastes after small amounts of a potentially dangerous additive were found to be present. Li Changjiang, the Minister of China's General Administration of Quality Supervision, Inspection and Quarantine, has publicly detailed the diplomatic headache caused by the bad international press these events have caused. His comments, published yesterday on the body's website, included the statement that: "Food safety work isn't just a law enforcement and vigilance involves the national image, it involves bilateral and even multilateral political relations." In light of these events, a statement has now been published on the Chinese Government's website, urging that: "Ensuring food and pharmaceutical safety for the public must be the starting point and destination of all work." Among the key features of the five-year overhaul plan detailed in the statement are dedicated inspections of the majority of food production firms, tough controls preventing over-use of pesticides and additives within the farming community and manufacturing industry, and the monitoring of adverse reactions to drugs across China. Regarding these elements, the online mission-statement advises that: "Monitoring and administering food and pharmaceutical safety must be at the very heart of grassroots and base work." The five-year plan stresses that, in years to come, "illegal activities behind production and sale of fake and shoddy foods and pharmaceuticals will be effectively contained...   more»

Sundia MediTech Company,Ltd. »06/06/2007 [Company watch]
China CROs Merge

Sundia MediTech and Shanghai United PharmaTech report that they will be merging. This is a first for China‚Äôs young CRO industry, acording to Sundia‚Äôs CEO, Wang Xiaochuan, Ph.D. Both Xiaochuan and United PharmaTech‚Äôs CEO, Shi Xiongwei, Ph.D., signed a letter of intent agreeing to combine their two companies. Under the terms of the merger, both United PharmaTech and Sundia MediTech will become subsidiaries of Sundia Investment Group, the British Virgin Islands-based holding company that currently owns Sundia MediTech. Dr. Wang will become the new company‚Äôs chairman and CEO, while Dr. Shi will hold the positions of director and executive vp. The former senior management teams of both companies will join together into a new, combined management team. Zhang Suyang, a partner of IDG VC, said that he believes China‚Äôs drug development CRO industry is beginning to emerge from its initial state into one in which companies will begin to consolidate. ‚ÄúThe CRO companies, and the overall size of the CRO industry in China are still relatively small, and there is huge potential for growth, so we can expect that in the following few years there will be many mergers,‚ÄĚ explained Zhang. ‚ÄúCompanies in this industry will grow quickly and soon; we will see companies of reasonable size and with good governance emerge as corporations with serious long-term potential.‚ÄĚ Part of the reason for the merger, noted Dr. Wang, is that it will combine United PharmaTech‚Äôs and Sundia‚Äôs technical expertise in different fields....   more»

Eli Lilly & Co »07/06/2007 [Company watch]
Lilly Announce $100 Million Investment in Research in China

Eli Lilly & Co, one of the world's leading pharmaceutical firms, plans to pour $100 million into China over the next five years to expand its drug research capacity in a bid to tap into the country's talent pool, its CEO said. The US drug maker will primarily beef up its research and development in biology, chemistry and clinical research areas, said John Lechleiter, president and CEO of Eli Lilly & Co....   more»

Charles River »10/06/2007 [Company watch]
Charles River Laboratories (CRL) will begin operating in China, establishing a joint venture with Shanghai BioExplorer Co., Ltd,

Charles River Laboratories (CRL) will begin operating in China, establishing a joint venture with Shanghai BioExplorer Co., Ltd, a Shanghai company that, like Charles River, provides pre-clinical CRO (Contract Research Organization) services. As one of the top two U.S. CROs, the menu of Charles River offerings are somewhat larger than BioExplorer's, although these will be expanded to meet the stated goal of supporting its customers‚Äô needs, from drug discovery through proof of concept on a global basis....   more»

Sundia MediTech Company,Ltd. »08/06/2007 [Company watch]
Sundia Meditech Company, Ltd. celebrated its recent strong growth at the company's third anniversary party in Shanghai.

The main business of this company is to provide contracted research (CRO) services to pharmaceutical and biotech company clients worldwide. Earlier this week, the company announced a merger in process with United Pharmatech Company, another CRO company in Shanghai....   more»

Eli Lilly & Co »06/06/2007 [Company watch]
BioVeda China today announced a $10 Million investment from Lilly Asian Ventures.

BioVeda China is the first international venture capital fund focusing on life sciences investments in China. The investment has shown Lilly's commitment to expand its economic footprint in the fast growing life science industry in China....   more»

Hutchinson Meditech
»20/06/2007 [Company watch]
Meditech Pays $3.3 Million for R&D Facility

Building in Zhang Jiang High-Tech Park in Shanghai Hutchinson MediPharma Ltd., a division of Hutchinson China Meditech Ltd. (London: HCM) (see story), purchased for $3.3 million the R&D facility in Shanghai it currently occupies....   more»

»18/06/2007 [Industry news]
Alpharma Inc. (ALO) Acquires Additional Animal Health Assets in China

BRIDGEWATER, NJ (MARKET WIRE) Jun 18, 2007 Alpharma Inc. (NYSE:ALO - News), a leading global specialty pharmaceutical company, announced it has acquired certain assets of Yantai JinHai Pharmaceutical Co. Ltd. located in Yantai City, Shandong Province, China....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.